Miller Glenn A
Genzyme Analytical Services, 3400 Computer Drive, Westborough, MA 01581, USA.
IDrugs. 2007 Mar;10(3):181-4.
The future of personalized medicine and the biopharmaceutical industry may lie in the close interaction between drug developers and clinical laboratories. The output of the Human Genome Project and other basic research into various diseases is generating data on individual variation in the treatment responses of patients; the biopharmaceutical industry and clinical laboratories will be expected to use this information to identify those patients who are best able to respond to a particular targeted therapy. Strategic partnerships between drug companies and clinical laboratories will be the centerpiece of this new era of medical treatment, providing higher-resolution diagnostics as well as more efficacious and safer treatment options.
个性化医疗和生物制药行业的未来可能在于药物研发人员与临床实验室之间的紧密互动。人类基因组计划及其他针对各种疾病的基础研究成果正在生成有关患者治疗反应个体差异的数据；预计生物制药行业和临床实验室将利用这些信息来识别那些最能对特定靶向治疗产生反应的患者。制药公司与临床实验室之间的战略合作伙伴关系将成为这个医疗新时代的核心，提供更高分辨率的诊断以及更有效、更安全的治疗选择。
